817 related articles for article (PubMed ID: 11922748)
41. Roles of NADPH-P450 reductase in the O-deethylation of 7-ethoxycoumarin by recombinant human cytochrome P450 1B1 variants in Escherichia coli.
Shimada T; Tsumura F; Gillam EM; Guengerich FP; Inoue K
Protein Expr Purif; 2000 Oct; 20(1):73-80. PubMed ID: 11035953
[TBL] [Abstract][Full Text] [Related]
42. Cooperativity in oxidations catalyzed by cytochrome P450 3A4.
Ueng YF; Kuwabara T; Chun YJ; Guengerich FP
Biochemistry; 1997 Jan; 36(2):370-81. PubMed ID: 9003190
[TBL] [Abstract][Full Text] [Related]
43. Drug metabolism by Escherichia coli expressing human cytochromes P450.
Parikh A; Gillam EM; Guengerich FP
Nat Biotechnol; 1997 Aug; 15(8):784-8. PubMed ID: 9255795
[TBL] [Abstract][Full Text] [Related]
44. Influence of ionic strength on the P450 monooxygenase reaction and role of cytochrome b5 in the process.
Schenkman JB; Voznesensky AI; Jansson I
Arch Biochem Biophys; 1994 Oct; 314(1):234-41. PubMed ID: 7944401
[TBL] [Abstract][Full Text] [Related]
45. Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3'-azido-3'-deoxythymidine (AZT) to 3'-amino-3'-deoxythymidine.
Pan-Zhou XR; Cretton-Scott E; Zhou XJ; Yang MX; Lasker JM; Sommadossi JP
Biochem Pharmacol; 1998 Mar; 55(6):757-66. PubMed ID: 9586947
[TBL] [Abstract][Full Text] [Related]
46. Effects of cytochrome b5 on cytochrome P-450-catalyzed reactions. Studies with manganese-substituted cytochrome b5.
Morgan ET; Coon MJ
Drug Metab Dispos; 1984; 12(3):358-64. PubMed ID: 6145564
[TBL] [Abstract][Full Text] [Related]
47. Effects of chronic exposure to cadmium on renal cytochrome P450-dependent monooxygenase system in rats.
Plewka A; Plewka D; Nowaczyk G; Brzóska MM; Kamiński M; Moniuszko-Jakoniuk J
Arch Toxicol; 2004 Apr; 78(4):194-200. PubMed ID: 14595535
[TBL] [Abstract][Full Text] [Related]
48. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.
Arbus C; Benyamina A; Llorca PM; Baylé F; Bromet N; Massiere F; Garay RP; Hameg A
Eur J Pharm Sci; 2007 Dec; 32(4-5):357-66. PubMed ID: 17951033
[TBL] [Abstract][Full Text] [Related]
49. Non-specific inhibition of human cytochrome P450-catalyzed reactions by hemin.
Kim EY; Kim JS; Kim MY; Koh WS; Guengerich FP; Yun CH
Toxicol Lett; 2004 Nov; 153(2):239-46. PubMed ID: 15451555
[TBL] [Abstract][Full Text] [Related]
50. Molecular characterization of specifically active recombinant fused enzymes consisting of CYP3A4, NADPH-cytochrome P450 oxidoreductase, and cytochrome b5.
Inui H; Maeda A; Ohkawa H
Biochemistry; 2007 Sep; 46(35):10213-21. PubMed ID: 17691855
[TBL] [Abstract][Full Text] [Related]
51. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
Robertson P; DeCory HH; Madan A; Parkinson A
Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
[TBL] [Abstract][Full Text] [Related]
52. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates.
Yamazaki H; Ueng YF; Shimada T; Guengerich FP
Biochemistry; 1995 Jul; 34(26):8380-9. PubMed ID: 7599128
[TBL] [Abstract][Full Text] [Related]
53. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification.
Buters JT; Shou M; Hardwick JP; Korzekwa KR; Gonzalez FJ
Drug Metab Dispos; 1995 Jul; 23(7):696-701. PubMed ID: 7587956
[TBL] [Abstract][Full Text] [Related]
54. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
55. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli.
Iwata H; Fujita K; Kushida H; Suzuki A; Konno Y; Nakamura K; Fujino A; Kamataki T
Biochem Pharmacol; 1998 Apr; 55(8):1315-25. PubMed ID: 9719488
[TBL] [Abstract][Full Text] [Related]
56. Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase.
Guengerich FP
Arch Biochem Biophys; 2005 Aug; 440(2):204-11. PubMed ID: 16055078
[TBL] [Abstract][Full Text] [Related]
57. Induction of cytochrome P450-dependent monooxygenases in hamster tissues by fasting.
Ueng TH; Ueng YF; Chen TL; Park SS; Iwasaki M; Guengerich FP
Toxicol Appl Pharmacol; 1993 Mar; 119(1):66-73. PubMed ID: 8470125
[TBL] [Abstract][Full Text] [Related]
58. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.
Venkatakrishnan K; von Moltke LL; Court MH; Harmatz JS; Crespi CL; Greenblatt DJ
Drug Metab Dispos; 2000 Dec; 28(12):1493-504. PubMed ID: 11095589
[TBL] [Abstract][Full Text] [Related]
59. Competitive interactions between cytochromes P450 2A6 and 2E1 for NADPH-cytochrome P450 oxidoreductase in the microsomal membranes produced by a baculovirus expression system.
Tan Y; Patten CJ; Smith T; Yang CS
Arch Biochem Biophys; 1997 Jun; 342(1):82-91. PubMed ID: 9185616
[TBL] [Abstract][Full Text] [Related]
60. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme.
Gillam EM; Baba T; Kim BR; Ohmori S; Guengerich FP
Arch Biochem Biophys; 1993 Aug; 305(1):123-31. PubMed ID: 8342945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
